Direct Plan · Growth Option · Sectoral / Thematic · Scheme code 135810
NAV₹37.3629as on 28 Oct 2026
Fund houseTata Mutual Fund
CategorySectoral / Thematic
Plan & optionDirect · Growth Option
History10.7 years
Returns (%)
1M
3M
6M
1Y
3Y
5Y
7Y
10Y
Launch
This scheme
0.28
8.57
13.31
12.43
20.85
15.37
23.35
15.30
13.83
Nifty 500 benchmark
0.87
4.31
2.15
5.20
12.49
11.41
—
—
15.49
Sectoral / Thematic category median
—
—
—
-5.63
13.04
10.23
—
13.74
—
Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
16.4%
0.88
1.47
0.80
9.97%
-19.8%
54.77
Nifty 500 benchmark
15.2%
0.39
0.58
—
—
-37.3%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
36 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
2,384
-17.3%
8.9%
76.3%
30%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
110%
63%
0.74
11.4%
0.77
18.41
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 36 months this scheme and
Nifty 500 share.
Tata India Pharma & Healthcare Fund
Direct Plan · Growth Option
Allocation
By asset
Equity
99.72%
Cash & Equivalents
0.28%
By market cap
Large Cap
26.01%
Mid Cap
33.87%
Small Cap
36.96%
Unclassified
2.88%
Concentration
Number of stocks
42
Top 5 stocks
30.18%
Top 10 stocks
50.53%
Top 20 stocks
77.09%
Lines in the filing
45
Largest holding
7.99%
Largest sector
Pharmaceuticals & Biotechnology 60.64%
Effective stocks
26.9
Sectors held
6
Cash
0.28%
Effective stocks is what the concentration works out to: a fund holding
42 names but most of its money in a few
behaves like a fund of 27. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Pharmaceuticals & Biotechnology
60.64%
Healthcare Services
27.79%
Fertilizers & Agrochemicals
6.93%
Chemicals & Petrochemicals
2.59%
Personal Products
1.23%
Healthcare Equipment & Supplies
0.54%
Cash & Equivalents
0.28%
Tata India Pharma & Healthcare Fund
Direct Plan · Growth Option · holdings
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
SUN PHARMACEUTICAL INDUSTRIES LTD
Pharmaceuticals & Biotechnology
665,178
121
7.99%
2
ABBOTT INDIA LTD
Pharmaceuticals & Biotechnology
33,086
90
5.94%
3
HEALTHCARE GLOBAL ENTERPRISES LTD
Healthcare Services
1,344,012
90
5.92%
4
DIVI LABORATORIES LTD
Pharmaceuticals & Biotechnology
92,361
86
5.68%
5
DR REDDYS LABORATORIES LTD
Pharmaceuticals & Biotechnology
570,312
70
4.65%
6
APOLLO HOSPITALS ENTERPRISE LTD
Healthcare Services
80,707
66
4.36%
7
RAINBOW CHILDRENS MEDICARE LTD
Healthcare Services
495,081
65
4.30%
8
CIPLA LTD
Pharmaceuticals & Biotechnology
473,861
64
4.22%
9
TORRENT PHARMACEUTICALS LTD
Pharmaceuticals & Biotechnology
118,503
57
3.76%
10
MAX HEALTHCARE INSTITUTE LTD
Healthcare Services
603,301
56
3.71%
11
LUPIN LTD
Pharmaceuticals & Biotechnology
233,454
47
3.14%
12
BAYER CROPSCIENCE LTD
Fertilizers & Agrochemicals
123,182
45
2.96%
13
SYNGENE INTERNATIONAL LTD
Healthcare Services
1,179,871
43
2.85%
14
PROCTER & GAMBLE HEALTH LTD
Pharmaceuticals & Biotechnology
74,596
42
2.75%
15
SAI LIFE SCIENCES LTD
Pharmaceuticals & Biotechnology
258,078
39
2.60%
16
PI INDUSTRIES LTD
Fertilizers & Agrochemicals
169,524
39
2.59%
17
ANTHEM BIOSCIENCES LTD
Pharmaceuticals & Biotechnology
452,985
39
2.57%
18
PFIZER LTD
Pharmaceuticals & Biotechnology
97,680
38
2.50%
19
ALKEM LABORATORIES LTD
Pharmaceuticals & Biotechnology
69,058
36
2.36%
20
FDC LTD
Pharmaceuticals & Biotechnology
997,013
34
2.24%
21
FORTIS HEALTHCARE LTD
Healthcare Services
382,994
29
1.95%
22
ACUTAAS CHEMICALS LTD
Pharmaceuticals & Biotechnology
89,770
29
1.95%
23
DR. LAL PATH LABS LTD
Healthcare Services
134,222
27
1.76%
24
ASTER DM QUALITY CARE LTD
Healthcare Services
362,442
25
1.67%
25
AJANTA PHARMA LTD
Pharmaceuticals & Biotechnology
68,052
25
1.63%
26
NATCO PHARMA LTD
Pharmaceuticals & Biotechnology
275,137
23
1.51%
27
SUMITOMO CHEMICAL INDIA LTD
Fertilizers & Agrochemicals
479,951
21
1.38%
28
GILLETTE INDIA LTD
Personal Products
26,534
19
1.23%
29
NAVIN FLUORINE INTERNATIONAL LTD
Chemicals & Petrochemicals
21,572
18
1.18%
30
IPCA LABORATORIES LTD
Pharmaceuticals & Biotechnology
71,536
14
0.91%
Tata India Pharma & Healthcare Fund
Direct Plan · Growth Option · where the money sits
What the manager did last month
Between the filings of 30 Jun 2026 and 31 Jul 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹101 cr
₹66 cr
5
2
+4.51%
Stock
Shares traded
Shares
Price
Value ₹ cr
New position
MANIPAL HEALTH ENTERPRISES LTD
253,500
entered
—
15.0
BASF INDIA LTD
41,008
entered
—
14.9
SANOFI CONSUMER HEALTHCARE INDIA LTD
18,363
entered
—
8.5
BIOCON LTD
187,500
entered
—
8.0
ANTHEM BIOSCIENCES LTD
1,400
entered
—
0.1
Added to
DR REDDYS LABORATORIES LTD
113,125
+24.7%
-15.4%
13.0
SYNGENE INTERNATIONAL LTD
275,422
+30.5%
-12.2%
10.6
PROCTER & GAMBLE HEALTH LTD
15,265
+37.1%
+4.4%
10.1
ABBOTT INDIA LTD
2,778
+9.8%
+9.3%
7.7
PFIZER LTD
15,746
+19.2%
+8.7%
7.6
SUMITOMO CHEMICAL INDIA LTD
144,241
+43.0%
+21.3%
7.4
GLAXOSMITHKLINE PHARMACEUTICALS LTD
25,788
+10.5%
+8.4%
6.9
DIVI LABORATORIES LTD
8,331
+7.4%
+22.5%
6.7
Trimmed
SANOFI INDIA LTD
54,633
-83.7%
-2.6%
18.1
MAX HEALTHCARE INSTITUTE LTD
160,969
-22.0%
-2.7%
17.7
APOLLO HOSPITALS ENTERPRISE LTD
10,152
-13.1%
+3.2%
9.1
MANKIND PHARMA LTD
31,614
-14.4%
-3.0%
7.8
METROPOLIS HEALTHCARE LTD
94,326
-24.1%
+7.8%
5.5
NEULAND LABORATORIES LTD
2,414
-19.2%
+2.5%
4.6
GLOBAL HEALTH LTD
22,586
-8.8%
+7.0%
3.2
Sold out of
TORRENT PHARMACEUTICALS LTD
32,086
exited
—
14.8
IPCA LABORATORIES LTD
50,000
exited
—
8.5
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹965,644
₹365,644
19.12%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment
Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 30 Oct 2026.
